Abstract
To summarize recommended treatment strategies for various dyslipidemias. The basic pathways of lipoprotein metabolism are reviewed, and the potential for interventional alterations to correct specific dyslipidemias is outlined. Guidelines for treatment based on published clinical trials, including the consensus report of the National Cholesterol Education Program, are discussed. The nonpharmacologic options of diet and exercise are important elements in the treatment of dyslipidemias. In most patients, a reduced dietary intake of fat (particularly saturated fat) should be maintained for 3 months before drug therapy is initiated. The various mechanisms of action of the bile acid resins, niacin, hydroxy-methylglutaryl-coenzyme A reductase inhibitors, and fibric acid derivatives are described, and their roles in monotherapy or combination therapy for hypercholesterolemia, combined hyperlipidemia, and hypertriglyceridemia are examined. With an understanding of the metabolic pathways responsible for the production and removal of lipoproteins and an overview of results of previous pharmacologic interventions, clinicians can optimize lipid-lowering treatment in individual patients with dyslipidemia.
References
Mar 7, 1992·Lancet·G F WattsA V Swan
Sep 15, 1992·The American Journal of Cardiology·G Assmann, H Schulte
Jul 1, 1992·The American Journal of Cardiology·C J GlueckJ Lang
Jan 1, 1992·Circulation·V ManninenM H Frick
Jul 21, 1990·Lancet·D OrnishK L Gould
Jan 1, 1991·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·M A Austin
Oct 1, 1990·American Journal of Epidemiology·J A Berlin, G A Colditz
Oct 4, 1990·The New England Journal of Medicine·H BuchwaldR D Smink
Nov 8, 1990·The New England Journal of Medicine·G BrownH T Dodge
Dec 19, 1990·JAMA : the Journal of the American Medical Association·J P KaneR J Havel
Oct 1, 1989·Journal of Internal Medicine·L A CarlsonA Asplund
Jul 7, 1988·The New England Journal of Medicine·S M Grundy
Jun 19, 1987·JAMA : the Journal of the American Medical Association·D H BlankenhornL Cashin-Hemphill
Nov 12, 1987·The New England Journal of Medicine·M H FrickV Manninen
Apr 4, 1986·Science·M S Brown, J L Goldstein
Jul 1, 1985·Metabolism: Clinical and Experimental·R H KnoppM Poole
Jul 1, 1973·The Journal of Clinical Investigation·J L GoldsteinA G Motulsky
Jan 20, 1984·JAMA : the Journal of the American Medical Association
May 1, 1983·Annals of Internal Medicine·H B BrewerE J Schaefer
Feb 15, 1994·The American Journal of Cardiology·J DavignonC Gagné
Apr 6, 1994·JAMA : the Journal of the American Medical Association·E J SchaeferR I Levy
Jun 1, 1994·Circulation·B L RodriguezD Chiu
Nov 15, 1993·Annals of Internal Medicine·D H BlankenhornUNKNOWN MARS Research Group
Mar 2, 1994·JAMA : the Journal of the American Medical Association·J M McKenneyV M Chinchili
Jun 14, 1993·Annals of the New York Academy of Sciences·W E ConnorS L Connor
Jan 1, 1993·The American Journal of Medicine·O WiklundS O Olofsson